Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03918447 · ClinicalTrials.gov registry record · Phase 3
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 667
- Enrollment target
NCT03918447 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 667 participants.
The verdict
NCT03918447, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 667 participants
- Enrollment target
Study Summary
This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.
Interventions
- DRUG Placebo oral capsule
- DRUG Bardoxolone methyl oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 667 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03918447
The ClinicalTrials.gov registry entry for NCT03918447 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 667 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03918447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03918447 about?
NCT03918447 is a clinical study titled "A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON". This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.
What is the current status of trial NCT03918447?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 667 participants. The study started on 2019-05-29. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT03918447?
The interventions under investigation include: Placebo oral capsule (DRUG), Bardoxolone methyl oral capsule (DRUG).
Who is sponsoring clinical trial NCT03918447?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.